✦ LIBER ✦

Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase IIB Neoadjuvant Study of Letrozole-Lapatinib in Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Operable Breast Cancer

✍ Scribed by Guarneri, V.; Generali, D. G.; Frassoldati, A.; Artioli, F.; Boni, C.; Cavanna, L.; Tagliafico, E.; Maiorana, A.; Bottini, A.; Cagossi, K.; Bisagni, G.; Piacentini, F.; Ficarra, G.; Bettelli, S.; Roncaglia, E.; Nuzzo, S.; Swaby, R.; Ellis, C.; Holford, C.; Conte, P.

Book ID: 126992570
Publisher: American Society of Clinical Oncology
Year: 2014
Tongue: English
Weight: 157 KB
Volume: 32
Category: Article
ISSN: 0732-183X
DOI: 10.1200/jco.2013.51.4737

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

An European Organisation for Research an

An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for Human Epidermal Growth Factor Receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer

✍ Bonnefoi, H.; Zaman, K.; Debled, M.; Fiche, M.; Fournier, M.; Nobahar, M.; Pierg 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 397 KB

RIBBON-1: Randomized, Double-Blind, Plac

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

✍ Brufsky, A. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 99 KB

RIBBON-1: Randomized, Double-Blind, Plac

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative, Locally Recurrent or Metastatic Breast Cancer

✍ Robert, N. J.; Dieras, V.; Glaspy, J.; Brufsky, A. M.; Bondarenko, I.; Lipatov, 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 317 KB

RIBBON-2: A Randomized, Double-Blind, Pl

RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

✍ Datko, F.M.; Dickler, M.N. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 295 KB